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Abstract
Background: Facioscapulohumeral muscular dystrophy (FSHD) is a dominantly-inherited progressive muscular
dystrophy caused by de-repression of the DUX4 gene, which causes disease by a toxic-gain-of-function. As
molecularly targeted drugs move from preclinical testing into human trials, it is essential that we validate clinical
trial tools and methodology to facilitate the drug development process.
Methods/design: The primary goal of this study is to hasten drug development for FSHD by validating two novel
clinical outcome assessments (COAs) and refining clinical trial strategies. We will perform an 18-month longitudinal
study in 220 genetically confirmed and clinically affected participants using our FSHD Clinical Trial Research Network,
comprised of 8 sites in the United States, and 3 collaborating sites in Europe. Visits occur at baseline and months 3, 12,
and 18. At each visit we will collect: 1) a novel FSHD functional composite COA made up of 18 evaluator-administered
motor tasks in the domains of shoulder/arm, hand, core/abdominal, leg, and balance function; and 2) electrical
impedance myography as a novel muscle quality biomarker (US sites). Other COAs include 1) Domain 1 of the Motor
Function Measure; 2) Reachable workspace; 3) orofacial strength using the Iowa Oral Performance Instrument; 4) lean
muscle mass using dual-energy X-ray absorptiometry (DEXA); 5) strength as measured by quantitative myometry and
manual muscle testing; and 6) the FSHD Health Index and other patient-reported outcomes. Plasma, DNA, RNA, and
serum will be collected for future biomarker studies. We will use an industry standard multi-site training plan. We will
evaluate the test-retest reliability, validity, and sensitivity to disease progression, and minimal clinically important
changes of our new COAs. We will assess associations between demographic and genetic factors and the rate of
disease progression to inform refinement of eligibility criteria for future clinical trials.
Discussion: To the best of our knowledge, this is the largest collaborative study of patients with FSHD performed in
the US and Europe. The results of this study will enable more efficient clinical trial design. During the conduct of the
study, relevant data will be made available for investigators or companies pursuing novel FSHD therapeutics.
Trial registration: clinicaltrials.gov NCT03458832; Date of registration: 1/11/2018
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Background
Facioscapulohumeral muscular dystrophy (FSHD) is the
second most common type of adult muscular dystrophy
with an estimated prevalence range of 2–12 per 100,000
[1]. It is mostly dominantly inherited, but new mutations
likely account for more than 10% of cases [2]. The disease
is characterized by slowly progressive, asymmetric weak-
ness that starts in the face and scapular muscles between
ages 15–30 [3]. It later progresses to involve the truncal
muscles and lower extremities, with about 20% of those
affected eventually using a wheelchair [4]. However, there
is a large degree of clinical variability in both disease pro-
gression and severity, even within families [3]. This makes
predicting an individual’s disease course difficult and has
made clinical trial design challenging.
The molecular defect in FSHD was discovered in 1992,
and is located in the D4Z4 region on chromosome 4q35,
a region with large repeated elements. The unified gen-
etic model suggests two necessary requirements for the
development of FSHD: 1) epigenetic de-repression of the
D4Z4 region, either through contraction of the D4Z4 re-
petitive element (normal individuals > 10 repeats; FSHD
1–10 repeats), or through a second mutation in a gene
involved in chromatin repression – both of which lower
methylation and open the chromatin structure in this re-
gion; and 2) a permissive 4qA polymorphism that in-
cludes a polyadenylation sequence just distal to the last
D4Z4 repeat. This results in de-repression of the Double
Homeobox 4 (DUX4) gene, which is contained in the
D4Z4 repeats and normally silenced in somatic cells [5].
DUX4 causes disease by a toxic gain-of-function. While
there are currently no effective pharmacological treat-
ments [6], this genetic model has provided targets for
drug development.
Drug development landscape
The unusual FSHD disease mechanism, the epigenetic
reactivation of the DUX4 gene, is particularly amenable
to knock-down of DUX4 using epigenetic strategies or
RNA therapies, as well as to other interventions target-
ing the downstream effects of DUX4 expression.
Current research involves the use of antisense oligo-
nucleotide therapies (ASOs) to target inactivation of
DUX4, and the success of ASOs for Duchenne muscu-
lar dystrophy (DMD) and spinal muscular atrophy pro-
vide a regulatory pathway for those chemistries [7, 8].
Exogenous siRNA targeting DUX4 transcription and
AAV-delivered RNA silencing of DUX4 are also being
investigated [9, 10], and some researchers are using
screens of small molecules to identify drugs that affect
D4Z4 methylation or translation of DUX4 [11]. Along
with molecular approaches to FSHD, non-specific ther-
apies that may provide a benefit on muscle mass or
function are also planned, and one placebo-controlled
trial of an anti-myostatin therapy is currently underway
(NCT02927080) [12].
Clinical trial readiness
The increasing pace of drug development has created a
pressing need for clinical trial preparedness. The import-
ance of clinical trial planning is evident in the recent ex-
perience of DMD where an incomplete understanding of
the 6min walk test, the primary outcome variable in
studies of premature stop and exon skipping therapies,
led to inconclusive studies and costly delays [13–15].
This difficulty as well as problems standardizing mea-
surements for biomarkers presented barriers as compan-
ies moved forward to try to gain FDA approval for
accelerated access or marketing [16, 17].
Meetings with industry, advocacy groups, and FSHD re-
searchers have identified several gaps in FSHD clinical
trial readiness. Other than manual muscle testing (MMT)
and quantitative myometry (QMT), there are no validated
outcome measures used consistently in clinical trials in
FSHD. A variety of individual functional measures have
been investigated, and while most of these measures are
reliable, none, individually, have been shown to be sensi-
tive to disease progression over 1 year [18, 19]. A func-
tional FSHD composite outcome measure (FSHD-COM)
was recently developed and is novel in that the selected
motor tasks reflect patient-reported significant domains of
functional impairment [4, 20]. It has shown high test-re-
test reliability and strong cross-sectional associations with
disease duration, clinical severity, and strength, but multi-
site reliability and sensitivity to disease progression are yet
to be demonstrated [21].
The identification and development of biomarkers
will also be important for future clinical trials, espe-
cially to accelerate early phase trials. There are studies
evaluating potential serum biomarkers but these are in
early stages [22, 23]. Imaging and electrodiagnostic bio-
markers are also being evaluated. Muscle MRI studies
in FSHD have demonstrated fatty infiltration and struc-
tural changes that could be quantified and followed
over time [24–27]. These structural changes demon-
strated strong cross-sectional correlations with mea-
sures of strength and function but longitudinal studies
assessing MRI changes over time are currently lacking
[24–26]. Electrical impedance myography (EIM) is
another tool that quantitatively and non-invasively
measures changes in muscle composition. It uses sub-
threshold electrical current to determine the impedance
to current flow through a particular muscle or muscle
group. It has shown good reliability and strong associa-
tions with measures of disease severity in diverse
neuromuscular diseases, including FSHD, spinal mus-
cular atrophy, and DMD, and is responsive to disease
progression in DMD and amyotrophic lateral sclerosis
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[28–32]. The potential advantages of EIM are readily
apparent when collecting the measurements. It is pain-
less, requires minimal training, and does not require
specific expertise in post-processing. It was found to
have good cross-sectional validity in FSHD [31]; how-
ever, a more recent study with 32 patients did not show
sensitivity to disease progression over 12 months in a
clinically relatively stable set of patients [33].
In addition to biomarker identification, there is a
broad consensus that a better understanding of the rela-
tionships between genetic and clinical features and dis-
ease progression may be helpful for refining trial
eligibility criteria. Previous cross-sectional studies have
identified possible genetic and demographic correlates of
disease progression. For instance, patients with the smal-
lest number of residual D4Z4 repeats generally have
more severe disease. These patients are typically diag-
nosed at a younger age, have higher penetrance by age
[34], are more likely to use a wheelchair [4, 35], and are
more likely to experience extra-muscular manifestations
of FSHD [36–38]. However, no prospective study has de-
termined whether such genetic differences have implica-
tions for disease progression over typical clinical trial
time frames.
Objectives
The overall aim of this study is to hasten drug develop-
ment for FSHD. To this end we will further develop two
novel clinical outcome assessments (COAs): the FSHD-
COM and a skeletal muscle biomarker, EIM. In addition,
we hope to gain a better understanding of the relation-
ships between genetic and demographic features and dis-
ease progression, which will be valuable for refining
eligibility criteria for future clinical trials. The specific
objectives are:
Objective 1: Determine the Multi-Site Reliability and
Validity of New COAs. We hypothesize that both the
FSHD-COM and EIM will be reliably measured at
multiple sites and reflect disease severity. Having
already established single site test-retest reliability and
convergent validity by examining associations between
the new COAs and other FSHD outcomes such as
strength and lean muscle mass, we will confirm these
findings in a large multi-site study.
Objective 2: Compare the Responsiveness of New COAs
to Those of Other FSHD Outcomes and Determine the
Minimal Clinically Important Changes (MCICs). We
hypothesize that our new COAs will be sensitive to
disease progression. We will determine the
responsiveness of our COAs to disease progression
over 12 and 18 months and compare it to those of
other FSHD outcomes, including strength and patient-
reported motor disability. We will determine the
variability in our COAs in a large cohort for sample
size calculations to plan future trials. We will use a
variety of techniques to determine the change in the
FSHD-COM that would be of minimal clinical
importance.
Objective 3: Establish FSHD Cohort Characteristics
Useful for Determining Clinical Trial Eligibility Criteria.
We hypothesize that known genetic and demographic
correlates of disease severity will account for some of
the variability in disease progression, and can help
refine trial eligibility criteria. Potential correlates of
disease progression include D4Z4 residual fragment
size, baseline functional status, age, and sex. We will
implement statistical methods to determine specific
subgroups of people with FSHD who are more or less
likely to progress over 12–18 months and use this
information to establish eligibility criteria for future
clinical trials.
Objective 4: Collect biological samples for future
biomarker studies. While this study will not directly
study tissue biomarkers, collecting serum, plasma,
RNA, and DNA from a large number of carefully
characterized FSHD patients followed for 18 months
provides a unique opportunity to create an invaluable
biorepository.
Methods/design
Study design
This is a prospective, multi-center, 18-month study of 220
FSHD patients. The study began recruitment in January,
2018 and the first patient was enrolled in March, 2018.
Recruitment and data collection is ongoing and will con-
tinue until 220 patients are enrolled. An established FSHD
Clinical Trial Research Network (FSHD-CTRN) [39], sup-
ported by the Muscular Dystrophy Association and the
FSH Society, with experienced clinicians and clinical evalu-
ators will be utilized to conduct the study (Fig. 1). The sites
were chosen for their wide geographic distribution, experi-
ence in neuromuscular clinical research in general and
FSHD in particular, prior collaborative work among the
sites, and access to a large number of patients with FSHD.
Protocol development and patient engagement
Collaboration with industry, advocacy groups, and
FSHD researchers played an important role in the
development of the current study. These meetings,
which included two clinical trial preparedness work-
shops, helped to identify the major gaps that need to
be addressed in order accelerate efficient drug devel-
opment [40, 41]. In addition to seeking guidance from
multiple sources prior to developing the protocol, col-
laboration and continued dialogue throughout the
course of the study has been a priority.
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We are using the FSHD-CTRN patient engagement
model to address specific aims or difficulties encoun-
tered in running the proposed study; for example, defin-
ing what would be clinically meaningful to people with
FSHD, addressing concerns related to participating in
clinical studies, and issues with recruitment and reten-
tion. We hope that this strategy will help mitigate attri-
tion bias. Specific feedback was sought from 2 to 4
individuals with FSHD at each CTRN site. Qualitative
data were analyzed to further refine areas of functional
importance to patients and the adequacy of functional
measures included in the current study. This feedback
was reviewed at the annual meeting. Continued feedback
will be sought in this manner throughout the duration
of the study.
Multi-site training plan
A pre-study multi-site training meeting was convened
in Year 1 to review the protocol and train clinical eval-
uators (CEs) and investigators. The CEs had a separate
hands-on training session on all study procedures, and
the Investigators had one for EIM training. At the
training sessions, intra-rater reliability was determined
by comparing performance on patient volunteers eval-
uated twice within a 24-h period. At wrap-up there
was open discussion of challenges encountered in test-
ing, discrepancies in results were discussed and re-
solved, and recommendations to improve reliability or
efficiency of testing were adopted. Hands-on training
was supplemented by access to videos demonstrating
proper procedures for functional and strength testing
and EIM. When new CEs or Investigators join the
study, they will be trained by webinar on techniques,
and then have in-person testing with the main CE
(FSHD-COM) or closest CTRN investigator (EIM).
Annual meetings will occur throughout the conduct of
the study to review the protocol, review recruitment
and challenges with achieving study goals, and refresh
training on the FSHD-COM and EIM testing. Our
plan to promote reliability of evaluation procedures is
modeled after an industry approach where a trained
lead Evaluator or Investigator trains site personnel to
promote consistency of technique and identify areas
requiring further training.
Subject recruitment and consent
Study subjects will be recruited through a variety of methods
which will help to lessen potential sampling bias. Subjects
will be identified using local neuromuscular patient lists, na-
tional and international FSHD registries, electronic health
record review at sites with Clinical Translational Science
Awards (CTSAs), and registration of the study on clinical-
trials.gov. In order to reach traditionally under-represented
populations, we will use local CTSA community outreach
officers to set up meetings with under-represented commu-
nities and discuss the study and study goals.
During the process of consent, after all study proce-
dures have been described and questions have been
answered, and prior to signing the informed consent
form, the subjects will be asked to describe their un-
derstanding of the study and their role in the study.
The study is voluntary, and subjects will be made
Fig. 1 Title: The FSHD-CTRN Legend: The FSHD-CTRN is made up of 8 US sites, with the University of Kansas Medical Center serving as the central
IRB and central coordinating center, and the University of Rochester serving as the data coordinating center. In addition, 3 collaborating sites in
Europe are participating in the study, with the exception that they will not be performing EIM. Source: http://www.kumc.edu/fshd/our-sites.html
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aware they can withdraw from the study at any time
for any reason.
Study population
The subject selection criteria are meant to yield the
types of subjects likely to be selected for FSHD clinical
trials; however, the criteria are still broad enough to in-
vestigate demographic and genetic factors that may be
associated with disease progression.
Inclusion criteria
Age 18–75; genetically confirmed FSHD1 or a clinical
diagnosis of FSHD with characteristic findings on exam
and an affected parent or offspring [42]; symptomatic
limb weakness; able to walk 30 ft without the support of
another person (canes, walking sticks, and braces are
allowed but not walkers); if taking over the counter sup-
plements, willing to remain consistent with the regimen
throughout the study.
Exclusion criteria
Cardiac or respiratory dysfunction that is deemed clinic-
ally unstable or would interfere with safe testing; ortho-
pedic conditions that preclude safe testing of muscle
function; regular use of muscle anabolic/catabolic agents
such as corticosteroids, oral testosterone or oral beta ag-
onists; use of an experimental drug in an FSHD clinical
trial within the past 30 days; and pregnancy.
We have not included patients with FSHD2 as they
represent only about 5% of the FSHD population and re-
cruitment of a sufficient number of these patients to ob-
tain meaningful results is not practical. It is possible that
individuals may inadvertently be enrolled who will sub-
sequently be found to have FSHD2, or an alternative
diagnosis. However, the expectation is that this will be
less than 5% of individuals without genetic confirmation
prior to enrollment. If genetic testing performed as part
of this study fails to confirm the genetic diagnosis, the
results of the genetic test will be shared with the partici-
pant, and their participation in the study will end.
Assessments
Enrolled subjects will be seen at the participating sites
for a two-day evaluation at the first visit and a single day
evaluation at each subsequent visit to include the sched-
ule of activities outlined in Table 1. To establish intra-
rater reliability at each site, all subjects will be reevalu-
ated using the FSHD-COM, Reachable workspace, Iowa
Oral Performance Instrument (IOPI), and EIM on Day 2
of Visit 1. In order to further characterize our cohort
with respect to disease severity and evaluate the validity
of the FSHD-COM and EIM, other evaluations will in-
clude MMT and QMT, dual energy X-ray absorpti-
ometry (DEXA) lean muscle mass, and two commonly
used FSHD clinical severity scales (The Clinical Severity
Score [CSS] and the FSHD Clinical Score [FCS]) [43,
44]. Patient-reported outcome measures including the
PROMIS57, the upper extremity functional index
(UEFI), the facial disability index (FDI) physical score
and the recently developed FSHD-Health Index (FSHD-
HI) will also be completed [20, 45–50].
FSHD-COM
The FSHD-COM is an 18-item evaluator-administered
instrument comprised of individually validated func-
tional motor tasks (Table 2) [21]. The body regions rep-
resented match areas of importance identified by
patients and include: leg function, shoulder and arm
function, trunk function, hand function, and balance.
The total scale has 72 points, with larger weight given to
the most commonly patient-noted areas of functional
concern – leg function and shoulder and arm function.
Each individual item is scored from 0 to 4, with 4 repre-
senting the worst performance and 0 corresponding to
unaffected/normal performance. While this composite
measure was intended to evaluate ambulatory patients, it
is still capable of capturing differences in functional per-
formance for those that are non-ambulatory, thus avoid-
ing any floor effects [21].
Electrical Impedance Myography (EIM)
EIM testing is non-invasive and will be administered by
a research study team member with proper training in
using EIM to assess the muscles of individuals with
neuromuscular disease. Prior studies have demonstrated
the reliability, validity, and sensitivity of EIM in FSHD in
a single site cohort [31, 33]. The tests are not considered
to involve more than minimal risk. The estimated testing
duration for an individual subject is 30 min.
EIM is administered using an investigational device
manufactured by Skulpt, Inc. (Boston, MA) that non-in-
vasively measures the impedance of skeletal muscle over
a frequency range between 1 kHz and 10MHz (Fig. 2).
The impedance is measured at each frequency by apply-
ing low-intensity electrical current (< 1 mA) via surface
electrodes; the resulting voltage signals are measured
using a second set of surface electrodes, converting them
into 2 impedance parameters, the resistance (R) and the
reactance (X). The device has shown excellent reliability
with intraclass correlations as high as 0.99 [31]. The full
measurement of a particular muscle includes the follow-
ing steps: 1) Applying saline to the surface of the skin
using a saline wipe; 2) Placing the EIM sensor on the
surface of the skin; and 3) Pressing a button on the de-
vice to begin a measurement. Each EIM measurement
takes 2–5 s. Typically, each muscle is tested 3 times to
make sure the measurement is repeatable. The following
bilateral muscles will be tested: deltoid, biceps, triceps,
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vastus lateralis, tibialis anterior, and medial
gastrocnemius.
Motor function measure domain 1 (MFM1)
The MFM Domain 1 is a validated evaluator-administered
functional measure for neuromuscular disorders, with 13
items related to standing position and transfers [68]. There
are standard instructions for administration and it takes
about 10min to perform.
Facial function
The IOPI is a means to quantify lip, tongue, and buccal
strength using a validated tool with published ranges for
normative data for lingual measurements [69]. For lip
strength testing, the IOPI bulb is placed between the lips
in midline and the subjects is instructed to squeeze the
lips together as hard as he/she can for 3–5 s (repeated 3
times with a 30 s interval between trials). Endurance
testing is conducted by asking the subject to hold 50% of
the maximum lip press for as long as possible while
viewing the light display on the IOPI to gauge 50%
effort. Similar procedures are executed to assess anterior
and posterior tongue and buccal strength and fatigue.
Reachable workspace
Subjects are seated in front of a stereo-camera and per-
form a standardized upper extremity movement proto-
col under the supervision of a study clinical evaluator
[70, 71]. Five hundred grams wrist weights are added.
The standardized simple set of movements consist of
lifting the arm from the resting position to above the
head while keeping the elbow extended, performing the
same movement in vertical planes at around 0, 45, 90,
and 135 degrees. The second set of movements consists
of horizontal sweeps at the level of the umbilicus and
shoulder. Each set of movements is repeated three
times for the left and right arms. A reduction in reach-
able workspace has previously been shown to reflect
upper extremity strength impairment in FSHD [70].
Strength testing
Strength testing will be performed using MMT, fixed QMT,
and maximal isometric hand grip strength using a hand held
Table 1 Schedule of assessments
Visits Visit 1 Visit 2 Visit 3 Visit 4
Day 1 Day 2
Time (Month) 0 3 12 18
+/− 1 Week +/− 2 Weeks +/− 2 Weeks
Obtain Consent X
Confirm Eligibility X
Urine Pregnancy Testa X X X X
History and Physical Exam X X X X
Blood for FSHD DNA Testing X X
Blood for Serum Extraction X X X X
Blood for RNA (PAX gene tube) X X
Blood for Plasma (EDTA tube) X X X X
PROs: FSHD-HI, PROMIS57, UEFI, and FDI physical score X X X
Electrical Impedance Myography X X X X X
FSHD-COM / MFM Domain 1 X X X X X
Strength Testing: QMT and MMT X X X X
Bedside spirometry X X X X
DEXA X X
Clinical Severity Scores X X X X
Iowa Oral Performance Instrument X X X X X
Reachable Workspace X X X X X
Fall/Exercise Questionnaire X X X X
Fall Assessmentb X
“Domain-delta” questionnaire X X
aUrine pregnancy test for women of childbearing age, b weekly × 12 weeks after the month 3 visit
Assessments occur at baseline, 3, 12, and 18 months. The FSHD-COM, electrical impedance myography, MFM Domain 1, Iowa Oral Performance Instrument, and
Reachable Workspace are performed on Day 1 and Day 2 of the baseline visit in order to establish intra-rater reliability
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force dynamometer [18, 49, 72]. For MMT a modified
Medical Research Council 10 point scale will be used – with
standardized positions for each muscle. QMT will be per-
formed using a fixed myometry testing system, with a force
transducer attached by an inelastic strap to a metal frame.
Respiratory function
We will obtain forced vital capacity and forced expira-
tory volume in 1 s, both standardized outcomes used
commonly in the clinic and in clinical trials.
DEXA
Whole body and regional lean muscle mass will be mea-
sured via DEXA. DEXA uses a very small amount of x-
ray energy (0.5 to 1.0 mREM vs. 20–30 mREM for a
chest x-ray) to measure body composition. DEXA pro-
vides a practical approach to estimate lean muscle mass
and has been utilized previously in clinical trials in
neuromuscular disease [63, 73]. Female participants will
have a pregnancy test performed prior to testing.
Severity scores
A limited physical exam and strength testing (MMT)
will be used to derive two FSHD clinical severity scores,
the Clinical Severity Score (CSS) and the FSHD Clinical
Score (FCS) [43, 44]. These severity scores both rank
weakness in the face, shoulders, arms, distal, and prox-
imal lower extremities on either a 10- (CSS) or 15-point
scale (FCS). Both have been shown to be reliable, and
have been used in genetic studies to identify mildly and
severely affected FSHD individuals.
Patient reported outcomes
The FSHD-HI questionnaire was designed to measure
both overall FSHD health-related quality-of-life and 14
separate subdomains including: 1) mobility and ambula-
tion; 2) fine motor and distal arm weakness; 3) proximal
upper extremity and shoulder limitation; 4) trunk weak-
ness; 5) FSHD-specific activity impairment; 6) emotional
distress; 7) FSHD-specific impaired body image; 8) cog-
nitive impairment; 9) social role dissatisfaction; 10) so-
cial role limitations; and FSHD-specific symptoms of:
11) fatigue; 12) pain; 13) communication difficulties/fa-
cial weakness; and 14) gustatory dysfunction. Each of
these subdomains has been previously identified by
FSHD patients as having the greatest importance to their
specific population and is represented by a specific block
of items [20, 50]. The PROMIS57 is an instrument de-
veloped by the NIH PROMIS initiative. It has been
tested in general populations and generates scores for
physical function, and the impact of physical limitations
on daily life [45, 49]. The UEFI 15 is a validated patient
reported measure for adults with upper extremity dys-
function [46, 47]. The FDI physical score is a short 5
item questionnaire that assesses the physical impact of
facial weakness [48]. A fall and exercise questionnaire
assesses average monthly falls and near falls, and average
weekly amount of exercise (see Additional file 1). A fall
assessment will be completed weekly for 3 months after
the month 3 visit. Subjects will be asked to respond to
an email every week, for 12 consecutive weeks, that asks
about any falls they have had over the past week. The
fall diary will be kept on a password-protected server
where the subjects will sign in and complete the fall
Table 2 The FSHD-COM
Region ITEM References
Leg function Sit to stand
without hands
[51–53]
6 Minute Walk [54–56]
Self-selected gait speed [57–59]
Go 30′ [49, 55, 60]
Ascend/ descend stairs [49, 55, 60]
Shoulder / arm function Shoulder Abduction (R/L) [18, 60, 61]
Shoulder Forward Flexion (R/L) [18, 60, 61]
Elbow Flexion (R/L) [18, 60, 61]
Don/doff Coat [62]
Trunk function Pick up a penny from floor [62]
Sit up with feet held [4]
Supine to sit [4]
Hand function Hand Grip Force Men [49, 63–65]
Hand Grip Force Women [49, 63–65]
Balance TUG: Timed up and Go [66, 67]
The FSHD-COM is an 18-item instrument comprised of individually validated
motor tasks. More weight is given to leg function and shoulder/arm function
which are the two most frequently cited areas of patient concern (table
modified from Eichinger et al. [21])
Fig. 2 Electrical Impedance Myography Legend: The EIM device
consists of a laptop computer connected to a portable
handheld sensor
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diary each week. A standard questionnaire will ask about
the effect of FSHD on work/occupation.
Anchor to determine minimal clinically important
changes
Participants will be asked to complete a self-assessment
“domain-delta” questionnaire at the 3- and 12-month
visits, which is designed to accompany the FSHD-HI
[20, 50]. The purpose of the “domain-delta” question-
naire is similar to that of a global rating of change
questionnaire in that it will determine each patient’s
perceived change in their health related quality-of-life
between baseline and follow up. This questionnaire will
inquire about total health as well as health related to 14
subdomains self-identified as important by patients
during development of the FSHD-HI [20].
Genetic testing
Genetic testing is a requirement for participation in the
study. Detailed genetic testing includes accurate measure-
ment of the D4Z4 repeat number on chromosome 4, deter-
mination of the A/B allele variants, and measurement of
D4Z4 methylation levels [74]. In particular, for this study
we will focus on the associations between D4Z4 repeat
number and measures of disease progression. We will also
evaluate the difference between the expected methylation
based on D4Z4 repeat units alone, and the actual measured
methylation values. With the assistance of prof. Silvère van
der Maarel’s laboratory in Leiden University Medical
Center, all patients in the study will have detailed genetic
testing. Each subject will have approximately 25mL of
blood collected at baseline and month 3 for genetic testing.
The 3-month sample will be stored for use as a back-up for
any lost samples, or for use in future studies (e.g. genome-
wide association studies). Two 2.5ml PAX gene tubes will
be collected at baseline. One will be sent to Leiden along
with blood for genetic testing and the other stored locally
at − 80 °C to be sent to the University of Rochester Medical
Center (URMC) biorepository. An additional PAX gene
tube will be collected at 3months and will be sent to the
URMC biorepository.
Serum and plasma extraction
All sites will implement an identical serum and
plasma collection protocol. At least one aliquot of
serum from each of 3 visits will be stored centrally at
URMC as part of an existing FSHD biorepository and
the remaining aliquots will remain at the respective
network site. The sera and plasma will be made avail-
able to researchers interested in studying serum bio-
markers along with anonymized clinical information.
Participants will have approximately 10 mL of blood
collected at each visit for serum extraction and 10 mL
of blood for plasma extraction.
Data collection
During the conduct of the study, data collected will in-
clude the minimum necessary to address study aims:
demographics, medical and medication histories, and
documentation of physical and functional examination
results. The study will utilize the infrastructure of the
Muscle Study Group’s (MSG) Data Coordination Center
(DCC) at URMC. The DCC will provide REDCap data
entry training to all site staff and provide password pro-
tected access to the database for anonymized data entry.
Sample size considerations
We will recruit 220 subjects with FSHD for this study, 160
from the US and 60 from European sites. It is expected
that there will be approximately 165 subjects who
complete evaluations at 18months. A sample size of 165
subjects with data at 18months will provide 90% power to
detect a standardized response mean of 0.254 in any of
our outcome variables using a paired t-test and a 5% sig-
nificance level (two-tailed). By comparison, the estimated
standardized response mean for the 12-month change in
composite MMT score in our natural history study of
FSHD was approximately − 0.30 [18]. Also, a sample size
of 220 subjects at the baseline visit will provide at least
90% power to detect correlations between the new COAs
(FSHD-COM and EIM) and existing outcomes of 0.22 or
greater using a test with a 5% significance level (two-
tailed). A sample size of 165 subjects will provide 90%
power to detect correlations that are only slightly larger
(0.25 or greater) between changes in outcomes over 18
months. Finally, a sample size of 220 subjects at baseline
will provide > 90% power to detect that an intraclass cor-
relation coefficient for test-retest reliability is significantly
greater than a null hypothesis value of 0.70 (minimum ac-
ceptable) when the true value is 0.79 or higher, using a
one-tailed test with a 5% significance level [75]. Within
each center, a sample size of 20 subjects at baseline will
provide > 80% power to detect that an intraclass correl-
ation coefficient for test-retest reliability is significantly
greater than a null hypothesis value of 0.70 (minimum ac-
ceptable) when the true value is 0.89 or higher, using a
one-tailed test with a 5% significance level [75].
Statistical considerations
Objective 1: reliability and validity
Test-retest reliability of the FSHD-COM and EIM mea-
surements (components and composite scores), for each
site and overall, will be quantified using intraclass correl-
ation coefficients computed using one-way random effects
models. Ninety-five percent lower confidence bounds will
be computed for these quantities. Transformations will be
attempted, if necessary, for outcomes that are not normally
distributed. Bland-Altman plots will also be used for graph-
ical examination of reliability [76]. The cross-sectional data
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obtained in 220 FSHD patients at baseline will be used to
describe the sample and examine the relationships between
the FSHD-COM and clinical severity scores (CSS, FCS),
MFM, different measures of patient reported function
(FSHD-HI and its subscales, PROMIS57, FDI, and UEFI),
strength (QMT and MMT composite scores), reachable
workspace, spirometry, IOPI, lean muscle mass, and D4Z4
deletion size. These bivariate associations will be examined
using standard correlation and regression analyses. It is hy-
pothesized that these associations will be moderate, but not
so strong that one would consider the FSHD-COM redun-
dant with the existing measures. A factor analysis will be
performed to examine the structure of the FSHD-COM
and determine whether the different components group to-
gether in a logical manner; Cronbach’s α will be used to as-
sess the internal consistency of the scale.
For EIM, the metrics of primary interest include the
reactance and phase at 50 kHz, 100 kHz, and the 50/
200 kHz ratio. The data will be analyzed on individual
muscles (or muscle groups) and on composite scores.
Associations between EIM-derived measures and
QMT measures in individual muscles (or muscle
groups) will be examined. Associations between the
composite EIM measure and the FSHD-COM, MFM,
clinical severity scores, measures of patient-reported
function, composite strength scores, reachable work-
space, spirometry, lean muscle mass, and D4Z4
deletion size will also be examined using standard cor-
relation and regression analyses.
Relationships between the new COAs and other vari-
ables such as age, gender, age at symptom onset, years
since symptom onset, and years since diagnosis will be
similarly examined, but these analyses will be more ex-
ploratory in nature since these associations are not ne-
cessarily expected to be strong.
Similar analyses will be performed to determine the asso-
ciations between changes in the new COAs and changes in
the other outcomes (clinical severity scores, measures of pa-
tient-reported function, composite strength scores, lean
muscle mass). Associations will be examined using the
changes from baseline to 12 and 18months; the associa-
tions among 18-month changes are expected to be stronger
than those among 12-month changes. In addition, it will be
of particular interest to examine the associations between
3-month changes in EIM outcomes and 12- and 18-month
changes in other outcomes (including EIM) to see if there
is support for the use of EIM as a predictive marker in
short-term early-phase clinical trials.
Objective 2: responsiveness to change over time and MCIC
Responsiveness of the outcome measures to change
over 12–18 months will be assessed. This is reasonable
under the assumption that measurable progression oc-
curs in FSHD over a period of 1 year, as previously
shown [18]. Paired t-tests will be used to test the null
hypothesis of zero mean change at both 12 and 18
months for each measure.
Various statistics can be used for quantifying respon-
siveness, and the effect size and standardized response
mean have been most highly recommended for this pur-
pose [77]. The effect size is defined as the mean change
divided by the standard deviation of the baseline value
[78]. The standardized response mean is defined as the
mean change divided by the standard deviation of the
changes from baseline [79]. For within-group (paired)
comparisons, as is the case here, the standardized re-
sponse mean is equivalent to the paired t-test (the two
differ only by a factor of the square root of the sample
size). The bootstrap resampling technique will be used
to perform formal statistical comparisons between differ-
ent outcome measures in terms of these two measures
of responsiveness [80].
Anchor-based and distribution-based methods will be
used to determine the minimal clinically important
changes (MCICs) on the FSHD-COM [81]. Mean re-
sponses on the FSHD-COM will be described for each
of the categories of the “domain delta” questionnaire
(e.g., unchanged, a little better, a lot better, etc.). Re-
ceiver operating characteristic (ROC) curve methods will
be used to select a cut-off for the 12-month change in
the FSHD-COM that is best at minimizing misclassifica-
tion error, i.e., best distinguishes those who indicate that
they are at least “a little better” on the “domain-delta”
questionnaire and those who indicate otherwise. The 12-
month changes in the FSHD-COM that correspond to
effect sizes ranging from 0.30 to 0.50 standard deviation
units will also be described and compared to the MCIC
identified by ROC curve methods. These analyses will be
repeated for 18-month changes and for other outcome
measures. Anchor-based and distribution-based methods
are well known to have their strengths and limitations
and examination of the results derived by both methods
will be useful in reaching consensus on recommenda-
tions in this regard for future trials in FSHD [81].
Objective 3: Baseline correlates of change over time.
Identification of factors contributing to the variability
of disease progression may help in the design of future
clinical trials. The outcomes of primary interest are
the changes from baseline to 12 and 18 months in the
FSHD-COM. The baseline variables of primary inter-
est include the FSHD-COM score, the composite EIM
measure, clinical severity scores, measures of patient-
reported function, composite strength scores, lean
muscle mass, age, gender, age at symptom onset, years
since symptom onset, and D4Z4 deletion size. A mul-
tiple regression model will be constructed, and
competing models will be evaluated using a best-sub-
sets regression technique, in conjunction with Akaike
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information criterion and the Bayesian information
criterion [82]. This information will be combined with
clinical judgment to arrive at a final model.
Another set of exploratory analyses will be performed
using regression trees to attempt to identify subgroups
of FSHD subjects who have different rates of progres-
sion. Regression trees use recursive partitioning to parti-
tion the sample into different subsets that have different
levels of mean change in the FSHD-COM [83]. A
strength of these methods is that a cross-validation pro-
cedure is available for checking the final tree, which can
be pruned back to avoid over-fitting.
Discussion
At its completion, ReSolve will be the largest international,
prospective, observational study in FSHD. In addition to
validating two novel COAs, the study will provide a better
understanding of functional, genetic, and demographic
correlates of disease progression. This information is crit-
ical for selecting valid and reliable outcome measures,
sample size calculations, specifying rational eligibility cri-
teria, and the efficient conduct of future clinical trials.
There are limitations to this study. Our sample of
FSHD patients may not be representative of the entire
population. For example, patients with significant dis-
ability will be underrepresented. We have excluded those
that are non-ambulatory since these patients will likely
be excluded in future clinical trials and so that all in-
cluded patients will be able to complete every assess-
ment. In addition, as a multi-site study with many
investigators and clinical evaluators, reliability is a con-
cern. To mitigate the magnitude of this problem, we
have implemented a training protocol similar to that
used in industry. Still, it is important to point out that
these are similar problems that would be faced in future
clinical trials.
This study also has several unique aspects that are
important to mention. This is the first study conducted
using the recently established FSHD-CTRN. With sup-
port from industry, FSHD researchers, and patients, the
network was formed as a broad collaborative effort to
find treatments for FSHD. In keeping with this mission,
continued collaboration and data sharing is essential.
The data from this study will be made available for any
investigator or company pursuing treatments for FSHD.
Additionally, the creation of a biorepository as part of
this study provides an invaluable resource for future re-
search. With this network in place, another goal is to
build a strong partnership with patients and their fam-
ilies. This is being accomplished by increasing patient
engagement in all aspects of the clinical trial process.
Patients were involved in defining what is clinically
meaningful to them as well as in addressing issues re-
lated to subject recruitment and retention. Overall, we
hope to leverage the strengths of the network and pa-
tient engagement in order to hasten drug development.
Specifically, this study will help to address the chal-
lenges in FSHD clinical trial preparedness due to
FSHD’s slow disease progression and lack of current
biomarkers that clearly correlate with disease activity
and severity.
Additional file
Additional file 1: Table S1 FSHD-CTRN ReSolve Investigators (DOCX 21
kb)
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